What the AMH test tells you about your fertility and what it does not

A clinically informed article explained what the Anti-Müllerian Hormone (AMH) test measures, why it has become widely used in fertility assessment, and — cru...

What Happened

A clinically informed article explained what the Anti-Müllerian Hormone (AMH) test measures, why it has become widely used in fertility assessment, and — crucially — why it must not be interpreted as a standalone fertility score.
AMH is produced by granulosa cells of preantral and small antral follicles in the ovaries. Its blood concentration reflects the size of the remaining primordial follicle pool — the ovarian reserve — making it a surrogate marker for a woman's remaining egg quantity.
The article stressed that AMH measures only quantity of eggs (ovarian reserve), not egg quality, which is the more decisive factor in achieving a successful pregnancy, particularly for women over 35.
Research specific to India has found that Indian women show a more rapid decline in AMH levels with age compared to Caucasian populations, with approximately 14.5% of women under 35 and 50.5% of women over 35 presenting with low AMH values (below 1.1 ng/mL) in fertility clinic data.
The key clinical message is that the body does not require a specific AMH level to achieve pregnancy; a low AMH test result in isolation should not be used to advise against attempting natural conception or to drive premature clinical interventions.

Static Topic Bridges

Anti-Müllerian Hormone (AMH) — Biology and Clinical Significance

AMH is a glycoprotein hormone in the transforming growth factor-beta (TGF-β) superfamily. In the female reproductive system, it is produced exclusively by granulosa cells of ovarian follicles at the preantral and early antral stages. Because these small follicles are not significantly influenced by fluctuations in gonadotropins across the menstrual cycle, AMH levels remain relatively stable — making the test drawable at any point in the menstrual cycle, unlike other ovarian reserve markers.

AMH measures ovarian reserve (quantity of remaining follicles), not egg quality.
Can be tested at any time in the menstrual cycle (unlike FSH/AFC which are cycle-phase sensitive).
Age-specific reference ranges: Generally considered "normal" above 1.1 ng/mL; "low" below 1.1 ng/mL; "very low" below 0.5 ng/mL (ranges vary between laboratories and ethnic populations).
AMH declines with age; it reaches near-undetectable levels around menopause.
AMH is also used to monitor ovarian response in IVF protocols and to screen for polycystic ovarian syndrome (PCOS), where AMH is typically elevated.
AMH does NOT predict the probability of natural conception, the likelihood of IVF success in isolation, or the timing of menopause with clinical precision.
Egg quality — which declines more steeply after age 35 — is not reflected in AMH levels; a woman may have high AMH but poor-quality eggs (e.g., in PCOS), or low AMH but higher-quality remaining eggs.

Connection to this news: The article raises an important health literacy concern: the commercial expansion of AMH testing in India has led to widespread misinterpretation, where a single low result triggers anxiety or unnecessary medical intervention. The clinical evidence does not support this usage.

Assisted Reproductive Technology (Regulation) Act, 2021 — India's Regulatory Framework

India enacted the Assisted Reproductive Technology (Regulation) Act, 2021 (ART Act), signed into law on December 18, 2021. It is the primary legislation governing fertility clinics, ART banks, and assisted reproduction procedures.

Objective: Regulate and monitor ART clinics and banks; prevent misuse; ensure ethical and safe delivery of ART services.
Two categories of ART clinics: Level 1 (intrauterine insemination/IUI only) and Level 2 (IVF and research), with distinct infrastructure and staffing requirements.
National ART and Surrogacy Board: Responsible for setting minimum standards for physical facilities, laboratory equipment, diagnostic equipment, and expert staffing. This is the apex regulatory body.
ART clinics are required to conduct tests to identify the cause of infertility as part of the clinical workup — AMH is among the tests that fall within this diagnostic landscape.
The Act prohibits abandonment of an embryo or gamete, sex selection, commercial surrogacy (governed separately by the Surrogacy (Regulation) Act, 2021), and sale of human embryos.
Companion legislation: Surrogacy (Regulation) Act, 2021 — governs altruistic surrogacy and prohibits commercial surrogacy.

Connection to this news: The diagnostic tests performed in ART settings — including AMH — are governed by the standards set under the ART Act. The article's concern about misinterpretation of AMH results points to the need for rigorous clinical protocols under this regulatory framework to prevent medically unnecessary interventions driven by a single biomarker.

CDSCO and Regulation of Diagnostic Tests in India

The Central Drugs Standard Control Organisation (CDSCO) is the national regulatory authority for drugs, medical devices, cosmetics, and diagnostics in India, functioning under the Ministry of Health and Family Welfare. Diagnostic kits and laboratory tests used to measure hormones such as AMH fall within its regulatory purview.

CDSCO functions under the Drugs and Cosmetics Act, 1940 (as amended), and the Medical Devices Rules, 2017.
In vitro diagnostic (IVD) kits — including immunoassay kits used to measure AMH levels — require CDSCO approval before they can be marketed in India.
Laboratory-developed tests (LDTs) used within individual laboratories are subject to National Accreditation Board for Testing and Calibration Laboratories (NABL) standards rather than direct CDSCO pre-market approval.
Indian Council of Medical Research (ICMR) also plays a role through clinical practice guidelines and research oversight on reproductive health diagnostics.
The cost of an AMH test in India ranges approximately from ₹900–₹1,500 depending on city and laboratory.

Connection to this news: The regulatory framework around diagnostics is relevant because unregulated or poorly standardised AMH assays can produce variable results across laboratories, compounding the risk of misinterpretation. Standardisation of AMH assay methodology is an unresolved issue even globally.

India's National Health Policy 2017 recognises reproductive and maternal health as a priority domain. The AMH test debate sits within a broader policy conversation about women's health autonomy, medicalisation of fertility, and equitable access to reproductive healthcare.

National Health Policy, 2017: Aims for universal health coverage; includes reproductive, maternal, newborn, child, and adolescent health (RMNCAH) as a pillar.
Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana (PMJAY): India's flagship health insurance scheme; reproductive health conditions are included in its benefit packages, though ART procedures largely remain outside its ambit.
The medicalisation of fertility through aggressive biomarker testing raises issues of informed consent, health literacy, and potential exploitation of patients — all dimensions of health equity and patient rights.
India's fertility rate has declined to 2.0 (below replacement level of 2.1) as per NFHS-5 (2019-21), with urban areas recording 1.6 — suggesting that fertility challenges operate in a dual context: demographic transition at the population level, and personal fertility distress at the individual level.

Connection to this news: The caution that AMH must not be read in isolation is not merely a clinical point — it reflects a social justice concern that inadequate health literacy combined with aggressive commercial testing can cause women psychological harm and drive unnecessary, expensive, and potentially harmful medical interventions.

Key Facts & Data

AMH: Produced by granulosa cells of preantral and small antral follicles; marker of ovarian reserve (quantity), not egg quality.
AMH reference levels (general): Normal above 1.1 ng/mL; low below 1.1 ng/mL; very low below 0.5 ng/mL (laboratory-specific).
Indian women: More rapid AMH decline with age than Caucasian women (published in multiple peer-reviewed studies).
Low AMH prevalence (Indian fertility clinic data): ~14.5% of women under 35; ~50.5% of women over 35.
ART (Regulation) Act, 2021: Enacted December 18, 2021; governs fertility clinics and ART banks.
Surrogacy (Regulation) Act: 2021; prohibits commercial surrogacy.
CDSCO: Regulatory authority for drugs, medical devices, and IVD kits under Drugs and Cosmetics Act, 1940.
AMH test cost in India: Approximately ₹900–₹1,500.
India's Total Fertility Rate (NFHS-5, 2019-21): 2.0 nationally; 1.6 in urban areas.
National Health Policy: 2017.
AMH can be tested at any point in the menstrual cycle — unlike FSH (Follicle-Stimulating Hormone) and antral follicle count (AFC), which are cycle-phase sensitive.